Protagonist Therapeutics (PTGX) FY2021 results: revenue $27 million, down 4.4% on the year
Protagonist Therapeutics, Inc. (PTGX) reported revenue of $27 million for fiscal 2021, the year ended 31 December 2021, down 4.4% on the year before. Net income was -$126 million, and diluted earnings per share $-2.71. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2022.
Revenue
$27 million
-4.4% on the year
FY2017FY2021
Operating margin
-460.0%
-225.4% a year earlier
FY2017FY2021
Net income
-$126 million
FY2017FY2021
Diluted EPS
-$2.71
FY2017FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-108
-72.5
-41.5
Capital expenditure
1.1
0.5
1.0
+133.8%
Free cash flow
-109
-73.0
-42.5
Free cash flow margin
-398.3%
-254.8%
-18395.7%
Cash from investing
-15.9
-91.0
-53.7
Cash from financing
130
248
46.0
-47.5%
Depreciation and amortisation
0.8
0.9
0.7
-14.2%
Share-based compensation
16.4
7.9
8.4
+107.6%
Diluted shares, weighted
46m
34m
n/a
+34.7%
Shares outstanding at period end
48m
44m
27m
+9.4%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
300
280
80.0
+7.3%
Debt
0.0
0.0
9.8
Operating lease liabilities
3.7
4.5
6.0
-18.7%
Other liabilities
44.0
40.4
59.2
+9.1%
Total liabilities and equity
348
324
155
+7.2%
Fixed assets
1.8
1.5
1.7
+23.0%
Investments
203
190
100
+6.7%
Cash and equivalents
124
117
33.0
+5.4%
Other assets
19.0
15.2
20.2
+25.0%
Total assets
348
324
155
+7.2%
10-K for the year ended 31 December 2021, filed 28 February 2022: the filing.